AIPPI 2021: Covid-19 bottlenecks

TheInternational Federation of Pharmaceutical Manufacturers & Associations’Komal Kalha says barriers to the Covid-19 vaccine are dose sharing, tradebarriers and country readiness, not IP

Catherine White - IPM

The proposed Trade-Related Aspects of IntellectualProperty Rights (TRIPs) Covid-19 patent waiver could be “a legal nightmare forthe entire legal community... and changing the law is not easy, even if youneed to change it for emergency proposals” so said the International Federationof Pharmaceutical Manufacturers & Associations’ (IFPMA) Komal Kalha, addingthat a waiver could have “a lot of jurisdictional and legal issue concerns”.